Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes

Diabetes and Metabolism

Volumn 31, Issue 3 I, 2005, Pages 233-242

  Gautier, J F ^a,b   Fetita, S ^a   Sobngwi, E ^a,b   Salaun Martin C ^c  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c Lilly France   (France)

Author keywords

Glucagon like peptide 1; Incretin hormones; Insulin; Type 2 diabetes

Indexed keywords

CJC 1131; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLIMEPIRIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; P 9301; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HORMONAL REGULATION; HORMONE RELEASE; HUMAN; HYPOGLYCEMIA; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SYNTHESIS; METABOLITE; MOUSE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIENT; PANCREAS CELL; PROTEIN DEGRADATION; RAT; REVIEW; SMALL INTESTINE; STOMACH ACID SECRETION; STOMACH DISEASE; STOMACH EMPTYING;

EID: 21744433419     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70190-8     Document Type: Review

References (58)

1. Moore B, Edie ES, Abram JH. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem J, 1906, 1, 28-38.
2. Labarre J, Still EU. Studies on the physiology of secretin. Further studies on the effect of secretin on the blood sugar. Am J Physiol, 1930, 91, 649-53.
3. Unger RH, Eisentraut AM. Entero-insular axis. Arch Intern Med, 1969, 124, 261-266.
4. Creutzfeldt W, Ebert R. New developments in the incretin concept. Diabetologia, 1985, 28, 565-73.
5. Gutniak M, Orkosv C, Holst JJ et al. Antidiabetogenic effect of glucagon-like peptide 1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Eng J Med, 1992, 326, 1316-22.
6. Nathan DM, Schreiber E, Fogel H et al. Insulinotropic actions of glucagon-like peptide 1 (7-37) in diabetic and nondiabetic subjects. Diabetes Care, 1992, 15, 270-6.
7. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1(7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia, 1993, 36, 741-4.
8. Egan JM, Bulotta A, Hui H, Perfetti R. GLP-1 receptor agonist are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev, 2003, 19, 115-23.
9. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide 1 and glucose dependent insulin releasing polypeptide. Endocrine Rev, 1995, 16, 390-410.
10. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology, 2002, 122, 531-44.
11. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology, 2001, 142, 521-7.
12. Yip RGC and Wolfe MM. GIP biology and fat metabolism. Life Sciences, 2000, 66, 91-103.
13. Holz GG and Chepurny OG. Glucagon-like peptide-1 synthetic analogues: new therapeutic agents for use in the treatment of diabetes mellitus. Current Med Chem, 2003, 10, 2471-83.
14. Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab, 1973, 37, 826-8.
15. Andersen DK, Elahi D, Brown JC, Tobin JD, Andres R. Oral glucose augmentation of insulin secretion: interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. J Clin Invest, 1978, 49, 152-61.
16. Vilsboll T, Hoist JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia, 2004, 47, 357-66.
17. Myiawaki K, Yamada Y, Yano H, et al. Glucose intolerance caused by a defect in the enteroinsular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA, 1999, 96, 14843-7.
18. Trumper A, Trumper K, Trusheim H, Arnold R, Goke B, Horsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signalling. Mol Endocrinol, 2001, 15, 1559-70.
19. Nauck MA. Is glucagon-like peptide 1 an incretin hormone? Diabetologia, 1999, 42, 373-9.
20. Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol, 1996, 31, 665-70.
21. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 (7-36): a physiological incretin in man. Lancet, 1987, 2, 1300-4.
22. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon like peptide-1 (7-36) amide infused at near physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab, 1993, 76, 912-7.
23. Nauck MA, Niedereichholtz U, Ettler R, Hoist JJ, Orskov C, Schmeigel WH. Inhibition of gastric emptying by physiological and pharmacological doses of exogenous glucagon-like peptide -1 (GLP-1) outweighs insulinotropic effects in healthy normoglycemic volunteers. Am J Physiol, 1997, 273, E981-E988.
24. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev, 2002, 18, 430-41.
25. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Hoist JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycaemia by exogenous glucagon-like peptide-1 (7-36) amide in type I diabetic patients. Diabetes Care, 1996, 19, 580-6.
26. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counter regulatory hormone responses, cognitive functions and insulin secretion during hyperinsulinemic stepped hypoglycaemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab, 2002, 87, 1239-46.
27. van Dijk G, Thiele TE. Glucagon-like peptide-1(7-36) amide: a central regulator of satiety and interoceptive stress. Neuropeptides, 1999, 33, 406-14.
28. Meier JJ, Gallwitz B, Schmidt WE, Nauck MA. Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol, 2002, 440, 269-79.
29. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intakes in humans. J Clin Invest, 1998, 101, 515-20.
30. Naslund E, Barkeling B, King N, Gutniak M, et al. Energy intake and appetite are suppressed by glucagon-like peptide 1 (GLP-1) in obese men. Int J Obes Relat Metab Disord, 1999, 23, 304-11.
31. Gutzwiller JP, Drewe J, Goke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol, 1999, 276, 1541-4.
32. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet, 2002, 359, 824-30.
33. Drucker DJ. Glucagon-like peptide-1 and the islet β-cell: augmenta-tion of cell proliferation and inhibition of apoptosis. Endocrinology, 2003, 144, 5145-8.
34. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide-1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology, 2003, 141, 5149-58.
35. Toft-Nielsen MB, Damholt MB, Madsbas S, et al. Determinants of the impaired secretion of glucagon-like peptide 1 in type 2 diabetes. J Clin Endocrinol Metab, 2001, 86, 3717-23.
36. Vilsboll T, Krarup T, Deacon CF, Madsbad S, et al. Reduced postprandial concentrations of glucagon-like peptide 1 in type 2 diabetic patients. Diabetes, 2001, 50, 609-13.
37. Nauck MA, Heisematt MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 (GLP-1) (7-36) amide but not of synthetic human gastric inhibitory polypeptide (GIP) in patients with type 2 diabetes mellitus. J Clin Invest, 1993, 30, 301-7.
38. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1-(7-36) amide) in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab, 1996, 81, 327-32.
39. American Diabetes Association. Prevention or delay of type 2 diabetes. Diabetes Care, 2004, 27 (suppl 1), S47-S53.
40. Agence Nationale d'Accréditation et d'Evaluation du Soin, ANAES. Suivi du patient diabétique de type 2 à l'exclusion du suivi des complications. Janvier 1999, 159 p.
41. Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS. Recommandations de bonne pratique. Traitement médicamenteux du diabète de type 2 (Diabète non insulinodépendant). Diabetes Metab, 1999, 25 (suppl 6), 1-79.
42. United Kingdom Prospective Diabetes Study 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ, 1995, 310, 83-8.
43. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regulatory Peptides, 2004, 117, 77-88.
44. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab, 2001, 281, E155-E161.
45. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab, 2003, 88, 3082-9.
46. Degn K, Brock B, Juhl CB, et al. Effect of intravenous infusion of Exenatide (Synthetic Exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycaemia. Diabetes, 2004, 53, 2397-403.
47. Fineman M, Bicsak T, Shen L, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin in patients with type 2 diabetes. Diabetes Care, 2003, 26, 2370-7.
48. De Fronzo R, Ratner R, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes [Abstract]. Diabetologia, 2004, 47 (suppl 1), A280.
49. Kendall D, Riddle M, Zhuang D, et al. Effects of Exenatide (Exendin-4) on glycemic control and weight in patients with type 2 diabetes treated with metformin and a sulfonylurea [Abstract]. Diabetologia, 2004, 47 (suppl 1), A279.
50. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care, 2004, 27, 2628-35.
51. Elbrond B, Jakobsen G, Larsen S. Pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN2211, a long acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care, 2002, 25, 1398-404.
52. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long acting glucagon-like peptide 1 analogue liraglutide (NN2211). Diabetes Care, 2004, 27, 1335-42.
53. Nauck MA, Hompesch M, Filipczak, et al. Liraglutide significantly improves glycemic control and reduces body weight compared with glimepiride as add-on to metformin in type 2 diabetes [Abstract]. Diabetes, 2004, 53 (suppl 2), A83.
54. Guivarch PH, Dreyfus JF, Mathi S, et al. CJC-1131, a long acting GLP-1 analog for Type 2 diabetes mellitus: clinical development update [Abstract] Diabetologia, 2004, 47 (suppl 1), A282.
55. Pratley R, Galbreath E. Twelve-week monotherapy with the DPP-4 inhibitor LAF237 improves glycemic control in patients with type 2 diabetes (Abstract]. Diabetes, 2004, 53 (suppl 2), A83.
56. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care, 2004, 27, 2874-80.
57. Herman GA, Peng-Liang Z, Dietrich B, et al. the DP-IV inhibitor MK-0431 enhances active GLP-1 and reduces glucose following an OGTT in type 2 diabetes [Abstract]. Diabetes, 2004, 53 (suppl 2), A82.
58. Heinz J, Glund K, Hoffmann T, et al. The DP IV-inhibitor P93/01 improves glucose tolerance in humans with HbA1c greater than 6.0 [Abstract]. Diabetes, 2004, 53 (suppl 2), A128.